Skip to main content
Top
Published in: Irish Journal of Medical Science (1971 -) 2/2024

22-09-2023 | Antiphospholipid Syndrome | Original Article

Non-criteria autoantibodies in antiphospholipid syndrome may be associated with underlying disease activity

Authors: Pınar Akyüz Dağlı, Abdulsamet Erden, Hakan Babaoğlu, Özlem Karakaş, Bahar Özdemir Ulusoy, Hatice Ecem Konak, Berkan Armağan, Şükran Erten, Ahmet Omma

Published in: Irish Journal of Medical Science (1971 -) | Issue 2/2024

Login to get access

Abstract

Background

Antiphospholipid syndrome (APS) is a systemic autoimmune disorder characterized by persistent antiphospholipid antibodies (aPLs) with arterial and venous thrombosis and/or pregnancy morbidity. In recent years, several studies have highlighted the potential role of non-criteria aPL in diagnosing APS patients.

Aim

This study aimed to determine the association of the presence of non-criteria aPL antibodies to the clinical and laboratory features of patients with a diagnosis of APS.

Methods

Eighty patients diagnosed with APS and under observation in the rheumatology clinic of Ankara City Hospital were assessed. Patient demographic and clinical features were meticulously recorded. Non-criteria antibodies tested in our center included antiphosphatidylserine IgA, antiphosphatidylserine IgM, beta 2 glycoprotein IgA, anti-cardiolipin IgA, antiphospholipid antibody IgG, and antiphospholipid antibody IgM. Antibodies from patients who were tested for at least one non-criteria antibody were documented.

Results

Out of 80 patients, 55 (68.8%) were tested for at least one non-criteria antibody, and 29 of those patients (52.7%) tested positive for at least one non-criteria antibody. The antiphospholipid antibody IgM and the beta 2 glycoprotein IgA were the most commonly tested non-criteria antibodies. Patients with non-criteria antibody positivity had a higher frequency of Ds DNA positivity and low complement (62.0% vs. 35.0%, p = 0.042; 69.0% vs. 38.0%, p = 0.023), respectively. In addition, positivity for anti-cardiolipin IgG and b2 glycoprotein IgG was significantly higher in the group positive for non-criteria antibodies (79% vs. 31%, p ≤ 0.001; 72.0% vs. 19%, p ≤ 0.001). There was no significant difference between the clinical features of patients with at least one positivity for non-criteria antibodies and those without.

Conclusion

Systemic lupus erythematosus (SLE) is the most commonly associated disease with APS, being present in approximately 35% of cases [1]. Since the majority of the patient group in our study had APS that was secondary to SLE, non-criteria antibody positivity may be linked to the immunological activity of SLE. Large multicenter studies are necessary to investigate the clinical significance of isolated/combined positivity for criterion/non-criteria aPLs.
Literature
1.
go back to reference Cervera R, Serrano R, Pons-Estel G et al (2015) Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients. Ann Rheum Dis 74(6):1011–1018CrossRefPubMed Cervera R, Serrano R, Pons-Estel G et al (2015) Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients. Ann Rheum Dis 74(6):1011–1018CrossRefPubMed
2.
go back to reference Tektonidou MG, Andreoli L, Limper M et al (2019) EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann Rheum Dis 78(10):1296–1304CrossRefPubMed Tektonidou MG, Andreoli L, Limper M et al (2019) EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann Rheum Dis 78(10):1296–1304CrossRefPubMed
3.
go back to reference Miyakis S, Lockshin MD, Atsumi T et al (2006) International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 4(2):295–306CrossRefPubMed Miyakis S, Lockshin MD, Atsumi T et al (2006) International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 4(2):295–306CrossRefPubMed
5.
go back to reference Hu C, Li S, Xie Z et al (2021) Evaluation of the diagnostic value of non-criteria antibodies for antiphospholipid syndrome patients in a Chinese cohort. Front Immunol 12:741369CrossRefPubMedPubMedCentral Hu C, Li S, Xie Z et al (2021) Evaluation of the diagnostic value of non-criteria antibodies for antiphospholipid syndrome patients in a Chinese cohort. Front Immunol 12:741369CrossRefPubMedPubMedCentral
6.
go back to reference Zohoury N, Bertolaccini ML, Rodriguez-Garcia JL et al (2017) Closing the serological gap in the antiphospholipid syndrome: the value of “non-criteria” antiphospholipid antibodies. J Rheumatol 44(11):1597–1602CrossRefPubMed Zohoury N, Bertolaccini ML, Rodriguez-Garcia JL et al (2017) Closing the serological gap in the antiphospholipid syndrome: the value of “non-criteria” antiphospholipid antibodies. J Rheumatol 44(11):1597–1602CrossRefPubMed
7.
go back to reference Sciascia S, Bertolaccini M (2014) Antibodies to phosphatidylserine/prothrombin complex and the antiphospholipid syndrome. Lupus 23(12):1309–1312CrossRefPubMed Sciascia S, Bertolaccini M (2014) Antibodies to phosphatidylserine/prothrombin complex and the antiphospholipid syndrome. Lupus 23(12):1309–1312CrossRefPubMed
8.
go back to reference Mekinian A, Bourrienne M-C, Carbillon L et al (2016) Non-conventional antiphospholipid antibodies in patients with clinical obstetrical APS: prevalence and treatment efficacy in pregnancies. Seminars in arthritis and rheumatism. Elsevier Mekinian A, Bourrienne M-C, Carbillon L et al (2016) Non-conventional antiphospholipid antibodies in patients with clinical obstetrical APS: prevalence and treatment efficacy in pregnancies. Seminars in arthritis and rheumatism. Elsevier
9.
go back to reference Liu X, Zhu L, Liu H et al (2022) Non-criteria antiphospholipid antibodies in antiphospholipid syndrome: diagnostic value added. Front Immunol 13:972012CrossRefPubMedPubMedCentral Liu X, Zhu L, Liu H et al (2022) Non-criteria antiphospholipid antibodies in antiphospholipid syndrome: diagnostic value added. Front Immunol 13:972012CrossRefPubMedPubMedCentral
10.
go back to reference Otomo K, Atsumi T, Amengual O et al (2012) Efficacy of the antiphospholipid score for the diagnosis of antiphospholipid syndrome and its predictive value for thrombotic events. Arthritis Rheum 64(2):504–512CrossRefPubMed Otomo K, Atsumi T, Amengual O et al (2012) Efficacy of the antiphospholipid score for the diagnosis of antiphospholipid syndrome and its predictive value for thrombotic events. Arthritis Rheum 64(2):504–512CrossRefPubMed
11.
go back to reference Sciascia S, Sanna G, Murru V et al (2015) The global anti-phospholipid syndrome score in primary APS. Rheumatology 54(1):134–138CrossRefPubMed Sciascia S, Sanna G, Murru V et al (2015) The global anti-phospholipid syndrome score in primary APS. Rheumatology 54(1):134–138CrossRefPubMed
12.
go back to reference Nakamura H, Oku K, Amengual O et al (2018) First-line, non-criterial antiphospholipid antibody testing for the diagnosis of antiphospholipid syndrome in clinical practice: a combination of anti–β2-glycoprotein I domain I and anti–phosphatidylserine/prothrombin complex antibodies tests. Arthritis Care Res 70(4):627–634CrossRef Nakamura H, Oku K, Amengual O et al (2018) First-line, non-criterial antiphospholipid antibody testing for the diagnosis of antiphospholipid syndrome in clinical practice: a combination of anti–β2-glycoprotein I domain I and anti–phosphatidylserine/prothrombin complex antibodies tests. Arthritis Care Res 70(4):627–634CrossRef
13.
go back to reference Litvinova E, Darnige L, Kirilovsky A et al (2018) Prevalence and significance of non-conventional antiphospholipid antibodies in patients with clinical APS criteria. Front Immunol 9:2971CrossRefPubMedPubMedCentral Litvinova E, Darnige L, Kirilovsky A et al (2018) Prevalence and significance of non-conventional antiphospholipid antibodies in patients with clinical APS criteria. Front Immunol 9:2971CrossRefPubMedPubMedCentral
14.
15.
go back to reference Shi H, Zheng H, Yin Y-F et al (2018) Antiphosphatidylserine/prothrombin antibodies (aPS/PT) as potential diagnostic markers and risk predictors of venous thrombosis and obstetric complications in antiphospholipid syndrome. Clin Chem Lab Med 56(4):614–624CrossRefPubMed Shi H, Zheng H, Yin Y-F et al (2018) Antiphosphatidylserine/prothrombin antibodies (aPS/PT) as potential diagnostic markers and risk predictors of venous thrombosis and obstetric complications in antiphospholipid syndrome. Clin Chem Lab Med 56(4):614–624CrossRefPubMed
16.
go back to reference Žigon P, Podovšovnik A, Ambrožič A et al (2019) Added value of non-criteria antiphospholipid antibodies for antiphospholipid syndrome: lessons learned from year-long routine measurements. Clin Rheumatol 38:371–378CrossRefPubMed Žigon P, Podovšovnik A, Ambrožič A et al (2019) Added value of non-criteria antiphospholipid antibodies for antiphospholipid syndrome: lessons learned from year-long routine measurements. Clin Rheumatol 38:371–378CrossRefPubMed
17.
go back to reference Radin M, Foddai SG, Cecchi I et al (2020) Antiphosphatidylserine/prothrombin antibodies: an update on their association with clinical manifestations of antiphospholipid syndrome. Thromb Haemost 120(4):592–598CrossRefPubMed Radin M, Foddai SG, Cecchi I et al (2020) Antiphosphatidylserine/prothrombin antibodies: an update on their association with clinical manifestations of antiphospholipid syndrome. Thromb Haemost 120(4):592–598CrossRefPubMed
18.
go back to reference Yin D, Chayoua W, Kelchtermans H et al (2020) Detection of anti-domain I antibodies by chemiluminescence enables the identification of high-risk antiphospholipid syndrome patients: a multicenter multiplatform study. J Thromb Haemost 18(2):463–478CrossRefPubMed Yin D, Chayoua W, Kelchtermans H et al (2020) Detection of anti-domain I antibodies by chemiluminescence enables the identification of high-risk antiphospholipid syndrome patients: a multicenter multiplatform study. J Thromb Haemost 18(2):463–478CrossRefPubMed
19.
go back to reference Ortona E, Capozzi A, Colasanti T et al (2010) Vimentin/cardiolipin complex as a new antigenic target of the antiphospholipid syndrome. Blood J Am Soc Hematol 116(16):2960–2967 Ortona E, Capozzi A, Colasanti T et al (2010) Vimentin/cardiolipin complex as a new antigenic target of the antiphospholipid syndrome. Blood J Am Soc Hematol 116(16):2960–2967
20.
go back to reference Zuo Y, Willis R, Papalardo E et al (2017) A unique antiphospholipid assay recognizing phospholipid mixture compared with criteria antiphospholipid immunoassays in lupus patients. Lupus 26(6):606–615CrossRefPubMed Zuo Y, Willis R, Papalardo E et al (2017) A unique antiphospholipid assay recognizing phospholipid mixture compared with criteria antiphospholipid immunoassays in lupus patients. Lupus 26(6):606–615CrossRefPubMed
21.
go back to reference Liu T, Gu J, Wan L et al (2020) “Non-criteria” antiphospholipid antibodies add value to antiphospholipid syndrome diagnoses in a large Chinese cohort. Arthritis Res Ther 22(1):1–11CrossRef Liu T, Gu J, Wan L et al (2020) “Non-criteria” antiphospholipid antibodies add value to antiphospholipid syndrome diagnoses in a large Chinese cohort. Arthritis Res Ther 22(1):1–11CrossRef
22.
go back to reference Bertolaccini ML, Amengual O, Andreoli L et al (2014) 14th International Congress on Antiphospholipid Antibodies Task Force. Report on antiphospholipid syndrome laboratory diagnostics and trends. Autoimmun Rev 13(9):917–930CrossRefPubMed Bertolaccini ML, Amengual O, Andreoli L et al (2014) 14th International Congress on Antiphospholipid Antibodies Task Force. Report on antiphospholipid syndrome laboratory diagnostics and trends. Autoimmun Rev 13(9):917–930CrossRefPubMed
23.
go back to reference Lakos G, Favaloro EJ, Harris EN et al (2012) International consensus guidelines on anticardiolipin and anti–2-glycoprotein I testing. Arthritis Rheum 64(1):1–10CrossRefPubMed Lakos G, Favaloro EJ, Harris EN et al (2012) International consensus guidelines on anticardiolipin and anti–2-glycoprotein I testing. Arthritis Rheum 64(1):1–10CrossRefPubMed
24.
go back to reference Zhu R, Cheng C-Y, Yang Y et al (2022) Prevalence of aPhosphatidylserine/prothrombin antibodies and association with antiphospholipid antibody profiles in patients with antiphospholipid syndrome: a systematic review and meta-analysis. Thromb Res 214:106–114CrossRefPubMed Zhu R, Cheng C-Y, Yang Y et al (2022) Prevalence of aPhosphatidylserine/prothrombin antibodies and association with antiphospholipid antibody profiles in patients with antiphospholipid syndrome: a systematic review and meta-analysis. Thromb Res 214:106–114CrossRefPubMed
25.
go back to reference Amengual O, Forastiero R, Sugiura-Ogasawara M et al (2017) Evaluation of phosphatidylserine-dependent antiprothrombin antibody testing for the diagnosis of antiphospholipid syndrome: results of an international multicentre study. Lupus 26(3):266–276CrossRefPubMed Amengual O, Forastiero R, Sugiura-Ogasawara M et al (2017) Evaluation of phosphatidylserine-dependent antiprothrombin antibody testing for the diagnosis of antiphospholipid syndrome: results of an international multicentre study. Lupus 26(3):266–276CrossRefPubMed
26.
go back to reference Vandevelde A, Chayoua W, de Laat B et al (2022) Added value of antiphosphatidylserine/prothrombin antibodies in the workup of thrombotic antiphospholipid syndrome: communication from the ISTH SSC Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibodies. J Thromb Haemost 20(9):2136–2150CrossRefPubMed Vandevelde A, Chayoua W, de Laat B et al (2022) Added value of antiphosphatidylserine/prothrombin antibodies in the workup of thrombotic antiphospholipid syndrome: communication from the ISTH SSC Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibodies. J Thromb Haemost 20(9):2136–2150CrossRefPubMed
27.
go back to reference Tonello M, Mattia E, Favaro M et al (2019) IgG phosphatidylserine/prothrombin antibodies as a risk factor of thrombosis in antiphospholipid antibody carriers. Thromb Res 177:157–160CrossRefPubMed Tonello M, Mattia E, Favaro M et al (2019) IgG phosphatidylserine/prothrombin antibodies as a risk factor of thrombosis in antiphospholipid antibody carriers. Thromb Res 177:157–160CrossRefPubMed
28.
go back to reference Alijotas-Reig J, Esteve-Valverde E, Ferrer-Oliveras R et al (2020) Comparative study of obstetric antiphospholipid syndrome (OAPS) and non-criteria obstetric APS (NC-OAPS): report of 1640 cases from the EUROAPS registry. Rheumatology 59(6):1306–1314CrossRefPubMed Alijotas-Reig J, Esteve-Valverde E, Ferrer-Oliveras R et al (2020) Comparative study of obstetric antiphospholipid syndrome (OAPS) and non-criteria obstetric APS (NC-OAPS): report of 1640 cases from the EUROAPS registry. Rheumatology 59(6):1306–1314CrossRefPubMed
29.
go back to reference Dima A, Caraiola S, Jurcut C et al (2015) Extended antiphospholipid antibodies screening in systemic lupus erythematosus patients. Rom J Intern Med 53(4):321–328PubMed Dima A, Caraiola S, Jurcut C et al (2015) Extended antiphospholipid antibodies screening in systemic lupus erythematosus patients. Rom J Intern Med 53(4):321–328PubMed
30.
31.
go back to reference Radway-Bright E, Ravirajan C, Isenberg D (2000) The prevalence of antibodies to anionic phospholipids in patients with the primary antiphospholipid syndrome, systemic lupus erythematosus and their relatives and spouses. Rheumatology 39(4):427–431CrossRefPubMed Radway-Bright E, Ravirajan C, Isenberg D (2000) The prevalence of antibodies to anionic phospholipids in patients with the primary antiphospholipid syndrome, systemic lupus erythematosus and their relatives and spouses. Rheumatology 39(4):427–431CrossRefPubMed
32.
go back to reference Szodoray P, Tarr T, Tumpek J et al (2009) Identification of rare anti-phospholipid/protein co-factor autoantibodies in patients with systemic lupus erythematosus. Autoimmunity 42(6):497–506CrossRefPubMed Szodoray P, Tarr T, Tumpek J et al (2009) Identification of rare anti-phospholipid/protein co-factor autoantibodies in patients with systemic lupus erythematosus. Autoimmunity 42(6):497–506CrossRefPubMed
33.
go back to reference Fischer K, Przepiera-Będzak H, Brzosko I et al (2022) Anti-phosphatidylethanolamine and anti-phosphatidylserine antibodies—association with renal involvement, atherosclerosis, cardiovascular manifestations, Raynaud phenomenon and disease activity in Polish patients with systemic lupus erythematosus. Biomolecules 12(10):1328CrossRefPubMedPubMedCentral Fischer K, Przepiera-Będzak H, Brzosko I et al (2022) Anti-phosphatidylethanolamine and anti-phosphatidylserine antibodies—association with renal involvement, atherosclerosis, cardiovascular manifestations, Raynaud phenomenon and disease activity in Polish patients with systemic lupus erythematosus. Biomolecules 12(10):1328CrossRefPubMedPubMedCentral
Metadata
Title
Non-criteria autoantibodies in antiphospholipid syndrome may be associated with underlying disease activity
Authors
Pınar Akyüz Dağlı
Abdulsamet Erden
Hakan Babaoğlu
Özlem Karakaş
Bahar Özdemir Ulusoy
Hatice Ecem Konak
Berkan Armağan
Şükran Erten
Ahmet Omma
Publication date
22-09-2023
Publisher
Springer International Publishing
Published in
Irish Journal of Medical Science (1971 -) / Issue 2/2024
Print ISSN: 0021-1265
Electronic ISSN: 1863-4362
DOI
https://doi.org/10.1007/s11845-023-03519-y

Other articles of this Issue 2/2024

Irish Journal of Medical Science (1971 -) 2/2024 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.